EP1235841A4 - Declenchement de reponses immunitaires cellulaires a mage2/3 au moyen de compositions de peptides et d'acides nucleiques - Google Patents

Declenchement de reponses immunitaires cellulaires a mage2/3 au moyen de compositions de peptides et d'acides nucleiques

Info

Publication number
EP1235841A4
EP1235841A4 EP00984183A EP00984183A EP1235841A4 EP 1235841 A4 EP1235841 A4 EP 1235841A4 EP 00984183 A EP00984183 A EP 00984183A EP 00984183 A EP00984183 A EP 00984183A EP 1235841 A4 EP1235841 A4 EP 1235841A4
Authority
EP
European Patent Office
Prior art keywords
mage2
triggering
peptide
nucleic acid
immune responses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00984183A
Other languages
German (de)
English (en)
Other versions
EP1235841A1 (fr
Inventor
John Fikes
Alessandro Sette
John Sidney
Scott Southwood
Robert Chesnut
Esteban Celis
Elissa Keogh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epimmune Inc
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc filed Critical Epimmune Inc
Publication of EP1235841A1 publication Critical patent/EP1235841A1/fr
Publication of EP1235841A4 publication Critical patent/EP1235841A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EP00984183A 1999-12-10 2000-12-11 Declenchement de reponses immunitaires cellulaires a mage2/3 au moyen de compositions de peptides et d'acides nucleiques Withdrawn EP1235841A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45829899A 1999-12-10 1999-12-10
US458298 1999-12-10
PCT/US2000/033545 WO2001042267A1 (fr) 1999-12-10 2000-12-11 Declenchement de reponses immunitaires cellulaires a mage2/3 au moyen de compositions de peptides et d'acides nucleiques

Publications (2)

Publication Number Publication Date
EP1235841A1 EP1235841A1 (fr) 2002-09-04
EP1235841A4 true EP1235841A4 (fr) 2006-04-12

Family

ID=23820224

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00984183A Withdrawn EP1235841A4 (fr) 1999-12-10 2000-12-11 Declenchement de reponses immunitaires cellulaires a mage2/3 au moyen de compositions de peptides et d'acides nucleiques

Country Status (5)

Country Link
EP (1) EP1235841A4 (fr)
JP (1) JP2003517310A (fr)
AU (1) AU2085001A (fr)
CA (1) CA2393339A1 (fr)
WO (1) WO2001042267A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7842480B2 (en) 2001-05-18 2010-11-30 Mayo Foundation For Medical Education And Research Chimeric antigen-specific t cell-activating polypeptides
US20060222656A1 (en) 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
FR2837837B1 (fr) * 2002-03-28 2006-09-29 Roussy Inst Gustave Epitopes peptidiques communs a des antigenes d'une meme famille multigenique
US7488793B2 (en) * 2003-09-22 2009-02-10 Ludwig Institute For Cancer Research Isolated peptide which binds to HLA-Cw*07 and uses thereof
EP2391635B1 (fr) 2009-01-28 2017-04-26 Epimmune Inc. Polypeptides de liaison de pan-dr et leurs utilisations
ES2533228T3 (es) * 2009-06-09 2015-04-08 Vaxon Biotech Identificación, optimización y uso de epítopos compartidos de HLA-B*0702 para inmunoterapia
KR101503341B1 (ko) * 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
JP6255360B2 (ja) * 2015-03-04 2017-12-27 ヴァクソン バイオテックＶａｘｏｎ Ｂｉｏｔｅｃｈ 共有ｈｌａ−ｂ＊０７０２エピトープの同定、最適化および免疫療法のための使用
LT3388075T (lt) * 2015-03-27 2023-11-10 Immatics Biotechnologies Gmbh Nauji peptidai ir peptidų deriniai, skirti naudoti imunoterapijai prieš įvairius navikus (seq id 25 - mrax5-003)
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
JP7642530B2 (ja) * 2018-09-04 2025-03-10 トレオス バイオ リミテッド ペプチドワクチン
EP4410304A4 (fr) * 2021-09-24 2025-08-27 Cha Vaccine Res Institute Co Ltd Composition de vaccin anti-cancer comprenant des peptides dérivés d'un antigène associé à une tumeur, et un adjuvant consistant en un lipopeptide et une substance immunoactive, et utilisation associée

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995022317A1 (fr) * 1994-02-16 1995-08-24 Cytel Corporation Compositions et procedes utilises pour induire une immunite par les lymphocytes t cytotoxiques
WO1997013858A2 (fr) * 1995-10-12 1997-04-17 Chiron Corporation Homologues de mage-3 du babouin, adn codant pour ceux-ci et technique d'utilisation associee
US5662907A (en) * 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
WO1999045954A1 (fr) * 1998-03-13 1999-09-16 Epimmune, Inc. Peptides de liaison de hla et leurs applications

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09502086A (ja) * 1993-08-06 1997-03-04 サイテル コーポレイション 完全ｍａｇｅ１遺伝子のクローニング及び特性決定
US5965535A (en) * 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US5965381A (en) * 1998-03-06 1999-10-12 Ludwig Institute For Cancer Research Delivery of proteins into eukaryotic cells with recombinant yersinia

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5662907A (en) * 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
WO1995022317A1 (fr) * 1994-02-16 1995-08-24 Cytel Corporation Compositions et procedes utilises pour induire une immunite par les lymphocytes t cytotoxiques
WO1997013858A2 (fr) * 1995-10-12 1997-04-17 Chiron Corporation Homologues de mage-3 du babouin, adn codant pour ceux-ci et technique d'utilisation associee
WO1999045954A1 (fr) * 1998-03-13 1999-09-16 Epimmune, Inc. Peptides de liaison de hla et leurs applications

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALTMAN J ET AL: "Phenotypic analysis of antigen-specific T lymphocytes", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 274, no. 5284, 4 October 1996 (1996-10-04), pages 94 - 96, XP002135711, ISSN: 0036-8075 *
DEL GUERCIO M-F ET AL: "Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T Helper Epitopes (PADRE) for antibody responses in vivo", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 15, no. 4, March 1997 (1997-03-01), pages 441 - 448, XP004094438, ISSN: 0264-410X *
See also references of WO0142267A1 *

Also Published As

Publication number Publication date
WO2001042267A1 (fr) 2001-06-14
CA2393339A1 (fr) 2001-06-14
AU2085001A (en) 2001-06-18
JP2003517310A (ja) 2003-05-27
EP1235841A1 (fr) 2002-09-04

Similar Documents

Publication Publication Date Title
EP1235841A4 (fr) Declenchement de reponses immunitaires cellulaires a mage2/3 au moyen de compositions de peptides et d'acides nucleiques
AU6226100A (en) Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
ZA989740B (en) Cyclic amino acids and derivatives thereof useful as pharmaceutical agents
ATE390439T1 (de) An einem thrombopoietin rezeptor bindende peptide und zusammensetzungen
DE69822160D1 (de) Verbesserte injektionsspritze
EP1336410A4 (fr) Preparations proteiniques a injecter
HUP0100100A3 (en) Hepatitis c inhibitor peptide analogues, pharmaceutical compositions comprising thereof and their use
EP1372721A4 (fr) Procede de balayage de banques d'affichage de peptides au moyen d'un affichage de minicellule
EE04099B1 (et) Hüpodermilise injektsiooni seade
DE69820460T2 (de) Injektionsgerät
DK0875252T3 (da) Formuleringer af aktiveret protein C
IL138468A0 (en) Solid lipophilic microparticles contining a protein or peptide drug
NZ305735A (en) Cyclic peptide antifungal agents, preparation and pharmaceutical compositions thereof
ID29577A (id) Protein pestisida
HRP950612B1 (en) PEPTIDE p277 ANALOGS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM
ZA9811316B (en) Novel hepatitis C virus NS5B protein
EP1173467A4 (fr) Peptides synthetiques issus de chimiokines
EP1163334A4 (fr) Polynucleotides et sequences d'acides amines derives de cellules de stroma
DE69705017D1 (de) Medikamente bindendes Protein
IT1319934B1 (it) Dispositivo d'iniezione di carburante
DE60040903D1 (de) Aminosäuren enthaltende albuminpräparationen
DE69816241D1 (de) Aktivierte peptide und konjugate
AU2088701A (en) Inducing cellular immune responses to p53 using peptide and nucleic acid compositions
PT949923E (pt) Composicoes farmaceuticas estabilizadas a base de quinupristina e de dalfopristina e sua preparacao
WO2001078796A3 (fr) Recepteur de la gonadoliberine de type ii et polynucleotides codant pour ce recepteur

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020621

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SOUTHWOOD, SCOTT

Inventor name: CHESNUT, ROBERT

Inventor name: CELIS, ESTEBAN

Inventor name: FIKES, JOHN

Inventor name: KEOGH, ELISSA

Inventor name: SETTE, ALESSANDRO

Inventor name: SIDNEY, JOHN

A4 Supplementary search report drawn up and despatched

Effective date: 20060227

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20061017